이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)

2026년 7월 13일 업데이트: Gao-Jun Teng, Zhejiang Cancer Hospital

Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial

This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.

Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.

The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

140

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Guangdong
      • Guangzhou, Guangdong, 중국, 510060
      • Guangzhou, Guangdong, 중국, 510317
        • Guangdong Second People's Hospital
        • 연락하다:
      • Guangzhou, Guangdong, 중국, 510168
        • Jinshazhou Hospital of Guangzhou University of Chinese Medicine
        • 연락하다:
      • Guangzhou, Guangdong, 중국, 511400
        • The Affiliated Panyu Central Hospital of Guangzhou Medical University
        • 연락하다:
      • Guangzhou, Guangdong, 중국, 524003
        • The Second Affiliated Hospital of Guangdong Medical University
        • 연락하다:
      • Jiangmen, Guangdong, 중국, 529030
        • Jiangmen Central Hospital
        • 연락하다:
          • Yuchuang Liang
          • 전화번호: +86 13322888181
          • 이메일: jmlyc@21cn.com
    • Hubei
      • Wuhan, Hubei, 중국, 430022
        • Wuhan Union Hospital of China
        • 연락하다:
    • Hunan
      • Changsha, Hunan, 중국, 410013
        • The Third XIANGYA Hospital of Central South University
        • 연락하다:
      • Changsha, Hunan, 중국, 410011
        • The Second Xiangya Hospital of Central South University
        • 연락하다:
    • Jiangxi
      • Ganzhou, Jiangxi, 중국, 341000
        • Ganzhou Hospital-Nanfang Hospital, Southern Medical University
        • 연락하다:
      • Nanchang, Jiangxi, 중국, 330209
        • The First Affiliated Hospital of Nanchang University
        • 연락하다:
    • Shandong
      • Qingdao, Shandong, 중국, 266000
        • The Affiliated Hospital of Qingdao University
        • 연락하다:
    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
        • 연락하다:
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310022
        • Zhejiang Cancer Hospital
        • 연락하다:
        • 연락하다:
        • 부수사관:
          • Jiaping Zheng
      • Jinhua, Zhejiang, 중국, 321000
        • Jinhua Municipal Central Hospital
        • 연락하다:
      • Lishui, Zhejiang, 중국, 323020
      • Ningbo, Zhejiang, 중국, 315010
        • Ningbo No.2 Hospital
        • 연락하다:
      • Ningbo, Zhejiang, 중국, 315048
        • Ningbo Medical Center Lihuili Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Age ≥18 years.
  2. Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
  3. No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
  4. At least one measurable intrahepatic lesion according to RECIST v1.1.
  5. ECOG performance status of 0 or 1.
  6. Child-Pugh class A liver function.
  7. Life expectancy ≥3 months.
  8. Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:

    • Absolute neutrophil count ≥1.5 × 10⁹/L;
    • Platelet count ≥75 × 10⁹/L;
    • Hemoglobin ≥90 g/L;
    • Serum albumin ≥30 g/L;
    • Total bilirubin ≤1.5 × upper limit of normal;
    • AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
    • TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
    • Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.

Exclusion Criteria:

  1. Diffuse infiltrative liver lesions.
  2. Contraindications to TACE.
  3. Allergy to intravenous contrast agent.
  4. pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
  5. Patients with HIV or syphilis infection.
  6. Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
  7. History of allogeneic organ transplantation.
  8. Severe dysfunction of the heart, kidney, or other organs.
  9. Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
  10. Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg. TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment. Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed. TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
활성 비교기: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles. After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks. Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Survival
기간: From randomization to death from any cause, assessed up to approximately 48 months
Overall survival is defined as the time from enrollment/randomization to death from any cause. Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
From randomization to death from any cause, assessed up to approximately 48 months

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-Free Survival
기간: From randomization to disease progression or death, assessed up to approximately 48 months
Defined as the time from randomization to disease progression or death from any cause. Participants without progression or death will be censored at the last date known to be progression-free.
From randomization to disease progression or death, assessed up to approximately 48 months
Time to Progression
기간: From randomization to disease progression, assessed up to approximately 48 months
Defined as the time from randomization to disease progression. Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
From randomization to disease progression, assessed up to approximately 48 months
Objective Response Rate
기간: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Disease Control Rate
기간: Assessed every 6 weeks ±7 days, up to approximately 48 months
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
Assessed every 6 weeks ±7 days, up to approximately 48 months
Incidence of Grade ≥3 Adverse Events
기간: From first dose of study treatment through 28 days after the last dose of study treatment
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
From first dose of study treatment through 28 days after the last dose of study treatment
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
기간: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer. Scores are linearly transformed to a 0 to 100 scale. For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning. For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
Baseline and during treatment/follow-up, assessed up to approximately 48 months
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
기간: Baseline and during treatment/follow-up, assessed up to approximately 48 months
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life. The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity. Higher scores in each dimension indicate more severe problems or worse health status.
Baseline and during treatment/follow-up, assessed up to approximately 48 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Gaojun Teng, MD, Zhejiang Cancer Hospital
  • 수석 연구원: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
  • 수석 연구원: Jiansong Ji, MD, The Central Hospital of Lishui City

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 7월 1일

기본 완료 (추정된)

2030년 1월 1일

연구 완료 (추정된)

2030년 7월 1일

연구 등록 날짜

최초 제출

2026년 6월 30일

QC 기준을 충족하는 최초 제출

2026년 6월 30일

처음 게시됨 (실제)

2026년 7월 9일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 14일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 13일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • RAINBOW 01

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

Individual participant data will not be shared due to privacy, ethical, and regulatory considerations.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .